News
Cannabis Research: 30,000 Studies and What’s Next
Add MyCannabis.com to your preferred sources on Google
Anyone familiar with medical cannabis research has likely heard the familiar refrain: “More research is needed to confirm these findings.” It is a careful way to temper promising results and avoid overstatement. For many readers, though, it leaves the impression that cannabis science is still in its infancy. A recent bibliometric study1 tells a different story. It shows a long, rich, and increasingly nuanced scientific record that stretches back nearly two centuries.
Cannabis Research Volume: Nearly 30,000 Studies
Between 1829 and 2021, researchers produced nearly 30,000 cannabis-related studies. Far from a niche topic, cannabis has appeared across close to 6,000 scientific journals, including:
- Journal of Drug and Alcohol Dependence — 706 publications
- Addictive Behaviors — 419 publications
- British Journal of Pharmacology — 356 publications
This body of work spans plant biology, chemistry, toxicology, public health, and clinical applications. The breadth alone challenges the idea that evidence is sparse.
Cannabis Research Trends: From Harms to Therapeutics
Swipe to scroll →
| Decade | Approx. Study Count | Primary Research Focus |
|---|---|---|
| 1829–1959 | < 500 | Basic plant biology, early pharmacology |
| 1960s–1980s | ~2,000 | Harms, toxicology, public health concerns |
| 1990s–2000s | ~8,000 | Endocannabinoid system, emerging medical uses |
| 2010s–2021 | ~19,000 | Therapeutics, harm reduction, product standardization |
The volume of cannabis publications rose sharply beginning in the 1960s. Early work largely focused on harms, reflecting the policies and culture of the time. Over recent decades, the scope broadened to examine therapeutic applications alongside risks. Modern reviews also lean on comprehensive databases such as Scopus to map trends more systematically.
Cannabis Research Funding and Its Impact on Study Focus
From 2000 to 2018, cannabis researchers received roughly $1.5 billion in funding. Much of this support came from agencies that historically emphasized identifying risks. That emphasis influenced research questions and sometimes the framing of conclusions. Even when studies reported potential benefits, authors often added cautious language about the need for confirmation. Caution is standard in science, but repeated use can reinforce the perception that the evidence base is thin.
Why Calls for More Cannabis Research Continue
With such a large literature, why the persistent qualifier? Several structural reasons stand out:
Regulatory complexity. Cannabis remains a controlled substance in many jurisdictions, which complicates clinical trial approvals and standardization.
Product variability. Strains, cannabinoid ratios, terpenes, and delivery methods vary widely, making it hard to compare outcomes across studies or set clinical dosing.
Trial design. Preclinical, observational, and real-world studies are abundant, but large randomized controlled trials are fewer in number, and these are often required for guideline-level recommendations.
What Current Cannabis Science Already Reveals
Thirty thousand studies do not equate to unanimous conclusions, yet they provide a substantial base for synthesis. Evidence now covers:
Mechanisms and pharmacology. Cannabinoids interact with the endocannabinoid system and other signaling pathways, helping explain effects on pain, inflammation, spasticity, and nausea.
Risk profiles. Studies clarify potential adverse effects, drug–drug interactions, and vulnerable populations. This improves harm-reduction guidance and informed consent.
Therapeutic signals. Multiple indications show signals of benefit that merit high-quality confirmatory trials. Policymakers and clinicians can use this to prioritize research and design better protocols.
The Future of Cannabis Research
The primary challenge is no longer a lack of studies. It is how to organize and apply what exists while filling the remaining gaps with rigorous, clinically focused research. As legal barriers ease and funding priorities diversify, expect greater standardization of products, more randomized trials, and improved translation of findings into practice.
For readers who want to explore the broader landscape, see additional context in our coverage of related findings here.
References
1. Ng, J. Y., & Chang, N. (2022). A bibliometric analysis of the cannabis and cannabinoid research literature. Journal of Cannabis Research, 4(1), 25. https://doi.org/10.1186/s42238-022-00133-0
